Driving innovation worldwide, leading the future of global health

We're GBIOLOGICS

Beyond new drug development, GBIOLOGICS is a global open‑innovation company rising onto the world stage with differentiated strategies. Through a collaborative network spanning Korea, China, Japan, and Northern Europe, we are accelerating the future of the biopharmaceutical industry.

Guided by our strategy — “Re‑Search, Connect/Develop, Speed‑to‑Market” — we discover innovative medicines and drive global commercialization. GBIOLOGICS continues to sow the seeds of hope for healthier lives worldwide.

History

Leveraging commercialization expertise, GBIOLOGICS accelerates market entry through optimized development

2025

  • Selected as a Baby Unicorn Company
  • Publication of GB910 in Molecular Therapy
  • GB910 U.S. Patent Registration
  • GB930 Korean Patent Registration
  • Winner of the Seoul–BMS Innovation Square Challenge

    • 2024

  • Completion of sGal‑9 GMP production
  • GB910 patent registrations (Japan and Australia)

    • 2023

  • Co-development agreement with Kolon Pharma for GB930

    • 2022

  • GLP‑TOX studies
  • Efficacy studies in SLE, RA, and Cancer

    • 2021

  • Co-development agreement with PLATBio for GB920
  • Series A funding secured: KRW 8.9 billion
  • GB910/RA indication patent registration

    • 2020

  • Establishment of sGal‑9 manufacturing process

    • 2019

  • Venture company certification (No. 20190402684)
  • Establishment of Coportate R&D center

    • 2018

  • Transfer of ownership for sGal‑9 material patents (U.S., Japan)
  • Establishment of GBIOLOGICS, Inc.

    • Timeline
    clients

    Leadership

    Experts with decades of strategic R&D and commercialization experience in the global pharmaceutical industry come together,
    creating synergy through their collective expertise

    David Song

    A leader with extensive biopharmaceutical expertise
    and strategic vision for global market success

    Professional background

    • College of Veterinary Medicine, SNU
    • Head of Biopharmaceutical Development
      of GC Biopharma & LG Chem
    • Founder & CEO of BIOCND

    Awards & Honors

    • Minister of Health and Welfare
    • Minister of Food and Drug Safety

    3rd Global recombinant hepatitis B vaccine commercialized

    1st US FTC approval  (Rota Vaccine) in Korea

    1st US FDA IND approval (PTH) in Korea

    2nd Global biosimilar (hGH) MA approval in US and EU

    Proven Track Record of Successful M&A and International Partnerships

    송영호

    Yeong Ho Song

    CSO

    30+ years of experience in Biopharma R&D and Business Development, Including IPOs and Capital Strategy

    • Life Science (MS), KAIST
    • Senior Researcher, LG Chem
    • Head of Bio Investment Team, ADL Partners
    강미숙

    Misuk Kang, PhD

    CTO

    15 + years of experience in Research and Clinical Development of Biologics

    • Pharmacology (PhD),
      University of Wisconsin-Madison
    • Principal Scientist, GSK & Novartis
    • Project Executive, GC Biopharma
    조시형

    Si Hyung Cho

    CFO

    20+ years of Leadership in Corporate Finance, M&A, and Strategic Capital Management

    • Statistics (BS), Dongguk University
    • General Accounting, Daewoo Corporation
    • General Manager of Finance , CJ Hello Vision
    clients
    Terms and Conditions

    GBIOLOGICS, Inc.

    Address: #3-202, Pangyo Seven Venture Valley Complex 1, 15 Pangyo-ro 228beongil, Bundang-gu, Seongnam-si, Gyeonggi-do 13487

    Phone: +82-31-600-7556
    FAX: +82-31-600-7555
    E-mail: info@gbiologics.com

    ©2025. GBIOLOGICS, Inc., All Rights Reserved.
    contact-section